The acquisition of non-pharma software assets signals potential strategic pivot or diversification. Monitor upcoming filings for any change in business description or capital allocation strategy. The 12-month lockup limits near-term selling pressure from the seller.
Price Chart
Executive Summary
Silo Pharma acquired software and IP assets marketed as 'Reputation Endpoints' from Larry King in exchange for 150,000 restricted shares of common stock, subject to a 12-month lockup. The deal is small in absolute terms and represents a diversification away from the company's core pharmaceutical focus. No financial terms beyond the share consideration were disclosed.
Key Facts
- Silo Pharma acquired software and related IP (the 'Reputation Endpoints' web-based tools) from Larry King.
- Consideration was 150,000 shares of Silo common stock, subject to a 12-month lockup.
- The shares were issued in a private placement exempt under Section 4(a)(2) of the Securities Act.
- The asset purchase agreement includes customary representations, warranties, and indemnification provisions.
- Exhibits A and B (detailed asset lists and open source software exclusions) were omitted from the filing.
Financial Impact
150,000 shares of common stock issued; no cash consideration. The dollar value depends on SILO's market price at issuance.
Risk Factors
- Diversification into software may dilute focus on core pharmaceutical pipeline.
- The acquired software's revenue contribution and strategic fit are unclear from the filing.
- No financial projections or performance metrics for the acquired assets were provided.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-109457 |
| Document: ea0308562-8k_silo.htm | 0001213900-26-109457 |
| Document: 0001213900-26-109457-index-headers.html | 0001213900-26-109457 |
| Document: 0001213900-26-109457-index.html | 0001213900-26-109457 |
| Document: 0001213900-26-109457.txt | 0001213900-26-109457 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $1.20 | awaiting T+60 | — | $1.20 (+0.00%) |
Oct 2, 2026 24d ago | 8-K | $1.49 | awaiting T+60 | — | $1.20 (−19.46%) |
Sep 18, 2026 5w ago | Press Release | $1.84 | awaiting T+60 | — | $1.20 (−34.78%) |
Aug 7, 2026 11w ago | EFFECT | $3.74 | awaiting T+60 | — | $1.20 (−67.87%) |
Jul 14, 2026 15w ago | Press Release | $5.13 $1.44 | ▼ −71.93% | ▼ −75.31% | $1.20 (−76.61%) |
Jun 30, 2026 17w ago | DEFA14A | $6.21 $1.77 | ▲ +71.50% | ▲ +75.06% | $1.20 (+80.68%) |
Jun 3, 2026 20w ago | 8-K | $6.11 $2.54 | ▼ −58.43% | ▼ −60.31% | $1.20 (−80.36%) |
Jun 1, 2026 21w ago | 8-K | $4.99 $2.59 | ▼ −48.09% | ▼ −49.32% | $1.20 (−75.95%) |
Apr 29, 2026 25w ago | Press Release | $6.74 $4.47 | ▼ −33.63% | ▼ −37.74% | $1.20 (−82.18%) |
Apr 22, 2026 26w ago | Press Release | $7.11 $4.70 | ▼ −33.90% | ▼ −38.91% | $1.20 (−83.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers